Innovation & intellectual property · 20/11/2009Updated: 10/17/2026 · 1 min read
USPTO Grants Interim Extension to Lucinactant Patent
Summary
The United States Patent and Trademark Office has issued an order granting a one-year interim extension to the term of U.S. Patent No. 5,407,914, which covers the medication SURFAXIN (lucinactant).
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →